Current Issues of Pharmacy and Medical Sciences

Prospective of ischemic stroke biomarkers

Curr Issues Pharm Med Sci., Vol. 30, No. 2, 69-74

Krzysztof Szewczak1, Magdalena Niespialowska1, Beata Jakubowska-Solarska1,
Magdalena Chalabis2, Jacek Gawlowicz3

Department of Hematological Diagnostics, Medical University of Lublin, Antoniego Gebali 6, 20-093 Lublin, Poland
2 Department of Laboratory Diagnostics, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland
3 Department of Neurology, Cardinal Rev. Wyszynski’s Voivodship Specialist Hospital in Lublin, Poland 


Methods currently used in brain vascular disorder diagnostics are neither fast enough nor clear-out; thus, there exists a necessity of finding new types of testing which could enlarge and complete the actual panel of diagnostics or be an alternative to current methods. The discovery of sensitive and specific biomarkers of ischemic brain stroke will improve the effects of treatment and will help to assess the progress or complications of the disease. The relevant diagnosis of ischemic stroke (IS) within the first 4.5 hours after the initial symptoms allows for the initiation of treatment with recombinant tissue plasminogen activators which limits the magnitude of negative changes in the brain and which enhance the final effectiveness of therapy. The potential biomarkers which are under investigation are substances involved in the processes of coagulation and fibrinolysis, and are of molecules released from damaged vascular endothelial cells and from nerves and cardiac tissue. The analyzed substances are typical of oxidative stress, apoptosis, excitotoxicity and damage of the blood brain barrier.


ischemic stroke, biomarker, inflammation, cytokines.


July 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31